ENHERTU Priority Review Boosts Daiichi Sankyo, AstraZeneca Breast Cancer Pipeline
Event summary
- The FDA granted Priority Review to ENHERTU (fam-trastuzumab deruxtecan-nxki) for post-neoadjuvant treatment of HER2-positive early breast cancer.
- The Priority Review follows Breakthrough Therapy Designation based on DESTINY-Breast05 trial data, showing a 53% reduction in invasive disease-free survival (IDFS) compared to trastuzumab emtansine (T-DM1).
- The FDA action date is July 7, 2026, with the sBLA reviewed under Project Orbis for concurrent international review.
- DESTINY-Breast05 demonstrated a three-year IDFS rate of 92.4% with ENHERTU versus 83.7% with T-DM1.
The big picture
The Priority Review for ENHERTU underscores the growing importance of antibody-drug conjugates (ADCs) in oncology, particularly for cancers with well-defined targets like HER2. This approval, if successful, could significantly shift the treatment paradigm for early breast cancer, a market representing billions in annual revenue. The DESTINY-Breast05 data represents a meaningful advance over existing therapies, but the long-term clinical and economic impact remains to be seen.
What we're watching
- Regulatory Risk
- The FDA’s decision in July 2026 will be critical; any unexpected rejection or significant concerns raised could impact investor confidence and future development plans for ENHERTU.
- Market Adoption
- The speed at which ENHERTU displaces T-DM1 in the post-neoadjuvant setting will depend on physician adoption and payer reimbursement decisions, potentially impacting peak sales projections.
- Clinical Expansion
- Daiichi Sankyo and AstraZeneca will need to demonstrate continued clinical success with ENHERTU across other cancer types and treatment settings to justify the significant investment in the ADC platform.
Related topics